TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for TransCode Therapeutics in a research note issued to investors on Wednesday, April 16th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.18) for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($4.76) per share.
TransCode Therapeutics Trading Down 23.6 %
Shares of RNAZ stock opened at $0.27 on Thursday. The firm’s 50 day moving average is $2.54 and its 200-day moving average is $168.66. TransCode Therapeutics has a 1 year low of $0.22 and a 1 year high of $66.33.
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Read More
- Five stocks we like better than TransCode Therapeutics
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- How to Invest in Small Cap Stocks
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
